pazopanib

P2/3, N=73, Active, not recruiting, National Cancer Institute (NCI) | N=190 --> 73 | Trial completion date: Mar 2030 --> Jan 2027

P2, N=180, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028

This case report is a valuable example of promising emerging systemic therapies for advanced DDCS, where the present standard of care lacks a repertoire of effective therapies.

This suppression of necroptosis was associated with reduced microgliosis, neuroinflammation and enhanced neuronal survival within the striatum. These findings highlight the potential of Pazo as a neuroprotective agent against HD by leveraging its antioxidant, anti-inflammatory, immune-modulating, and anti-necroptotic properties.

Despite the small sample size and absence of functional experiments, our results suggest that Pazopanib promotes cytotoxic immune programs but, by six months, reprograms PLT-EVs towards different adhesion characteristics contributing to Treg and MDSC expansion while suppressing NK activity. PLT-EVs may influence the balance between immune activation and suppression during anti-angiogenic therapy, suggesting PLT-EVs as biomarkers and therapeutic targets in mRCC.

The chemotherapy regimen of ifosfamide, mesna and doxorubicin proved effective for this condition, leading to a significant reduction in tumour size and metabolic activity. However, due to disease recurrence and the presence of a KDM5A-positive marker, second-line therapy with trabectedin and pazopanib became necessary.

This external validation confirms the seven-gene signature as a potential biomarker for predicting ICI efficacy in advanced sarcomas. Prospective studies are needed to determine the prognostic versus predictive value of SIGNIOS, refine its use across sarcoma subtypes, and explore its applicability in other tumor types.

P1/2, N=80, Active, not recruiting, University Hospital, Bordeaux | Recruiting --> Active, not recruiting | N=59 --> 80 | Trial primary completion date: Nov 2026 --> Aug 2025

Radiation-associated laryngeal angiosarcoma is exceptionally rare and portends a poor prognosis. This case illustrates the potential value of genomically informed multimodal therapy integrating chemotherapy, immunotherapy, and targeted agents; in our patient, toripalimab plus gemcitabine/nab-paclitaxel achieved a 9-month partial response. Further studies are needed to establish evidence-based treatment strategies for this understudied disease.

This case underscores the aggressive potential of dedifferentiated SFTs and highlights the diagnostic role of NAB2::STAT6 fusion. It emphasizes the importance of multidisciplinary care in managing rare, high-risk tumors of the bone.

Pediatric STS are rare and biologically heterogeneous. Genomic advances have refined risk stratification and uncovered therapeutic targets; further progress relies on international collaboration and trials.

Finally, tumouroids were subjected to treatment with Pazopanib (Votrient™), a tyrosine kinase inhibitor (TKI) used in the treatment of advanced RCC...Tumouroids mimic the original tumour and its microenvironment and elicit response to drugs that target both the tumour cells and the tumour microenvironment. This is a patient-specific in vitro tool that addresses the unmet clinical need for predicting an individual's response to therapy.